Allelica in a $1.8 million round backed by Valor Ventures and Pi Campus.

Allelica, a Rome, Italy and New York City-based genomics software company specializing in developing polygenic risk scores (PRSs) for common diseases, announced that it raised $1.75 million in seed financing.

The money was raised from investors led by Valor Ventures, joined by Sternberg Health, Pi Campus, and business angels whose name was not disclosed.

As part of the transaction, Valor Ventures General Partner Gary Peat has joined the Allelica board of directors and Allelica has relocated its headquarters to New York City.

The proceeds of the financing will be used to advance clinical integration of the company’s PRS software into healthcare systems in the US.

Allelica, founded in 2018 by Giordano Bottà (CEO), George Busby and Paolo Di Domenico, developed digital tools for estimating an individual’s PRS for multiple diseases, including coronary artery disease (CAD), breast cancer, prostate cancer, colon cancer, Type 2 diabetes and Alzheimer’s disease. A PRS is a measurement of a person’s risk of disease based on their genes and is based on combining the effects of a large number of genetic variants across the genome. This information can be used to stratify individuals based on their risk of disease. By combining PRS with conventional risk factors, Allelica believes precision medicine at scale can be achieved.

Allelica was previously preseeded by Pi Campus in 2018.